Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca.

John SheppardMark BergmannBarry A SchechterJodi I LuchsAbayomi OgundelePaul M Karpecki

Published in: Clinical ophthalmology (Auckland, N.Z.) (2021)

Registered at ClinicalTrials.gov on July 27, 2016. NCT02845674 https://clinicaltrials.gov/ct2/show/NCT02845674?term=OTX-101&draw=2&rank=1.

Keyphrases